U.S. Markets closed

Obalon Therapeutics, Inc. (OBLN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.8799+0.0287 (+3.37%)
At close: 12:59PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8512
Open0.8664
Bid0.8805 x 2200
Ask0.8860 x 3000
Day's Range0.8591 - 0.8860
52 Week Range0.6200 - 2.1400
Volume75,964
Avg. Volume133,131
Market Cap6.837M
Beta (5Y Monthly)-0.93
PE Ratio (TTM)N/A
EPS (TTM)-2.0610
Earnings DateNov 06, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.75
  • Is Obalon Therapeutics, Inc. (OBLN) A Good Stock To Buy?
    Insider Monkey

    Is Obalon Therapeutics, Inc. (OBLN) A Good Stock To Buy?

    After several tireless days we have finished crunching the numbers from nearly 817 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]

  • Obalon Announces Third Quarter 2020 Financial Results
    GlobeNewswire

    Obalon Announces Third Quarter 2020 Financial Results

    SAN DIEGO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter ended September 30, 2020. Financial results for the third quarter of 2020Revenue for the third quarter of 2020 was $44,000, compared to $0.3 million for the third quarter of 2019, with the decrease primarily due to the suspension of operations in the second quarter of 2020. Net loss for the third quarter of 2020 was $1.6 million, compared to $3.7 million for the third quarter of 2019. Net loss per share for the third quarter of 2020 was $0.20, compared to $0.61 for the third quarter of 2019.Cost of revenue was $41,000 for the third quarter of 2020, down from $0.4 million for the third quarter of 2019. Gross profit for the third quarter of 2020 was $3,000 compared to a gross deficit of $0.1 million for the third quarter of 2019.Research and Development expense for the third quarter of 2020 totaled $0.3 million, down from $1.2 million for the third quarter of 2019. Selling, General and Administrative expense decreased to $1.3 million for the third quarter of 2020, compared to $2.5 million for the third quarter of 2019.Operating loss for the third quarter of 2020 was $1.6 million, down from a loss of $3.7 million for the third quarter of 2019.As of September 30, 2020, the Company had cash and cash equivalents of $5.5 million and $0.4 million of debt related to its Payroll Protection Program loan. The Company intends to continue exploring the potential for third-party reimbursement for the Obalon Balloon System, as well as exploring and evaluating financial alternatives to help meet its capital needs and strategic alternatives that might enhance stockholder value. There is no assurance that any financial or strategic alternative will be identified. If the Company is not able to raise additional capital to meet its needs or to identify a suitable strategic alternative, it will have to discontinue all operations and may be required to declare bankruptcy or dissolve.About Obalon Therapeutics, Inc. Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.Cautionary Statement Regarding Forward Looking StatementsThis press release contains forward-looking statements that are not purely historical regarding Obalon’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to new products and their potential benefits. All forward-looking statements and reasons why results might differ included in this press release are made as of the date of this release, based on information currently available to Obalon, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward looking statements. The risks and uncertainties that may cause actual results to differ materially from Obalon’s current expectations are more fully described in Obalon’s annual report on Form 10-K for the period ended December 31, 2019, periodic reports on Form 10-Q for the periods ended September 30, 2020, June 30, 2020 and March 31, 2020 and its other reports, each as filed with the Securities and Exchange Commission. Except as required by law, Obalon assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results.OBALON THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) (in thousands, except shares and per share data) Three Months Ended September 30,  Nine Months Ended September 30,  2020  2019  2020  2019                                   Revenue$44  $333  $1,527  $2,494  Cost of revenue 41   412   1,005   2,323  Gross profit (deficit) 3   (79)  522   171  Operating expenses:                Research and development 271   1,174   2,293   5,401  Selling, general and administrative 1,291   2,489   7,546   13,025  Asset impairment and other charges —    —   1,310    —  Total operating expenses 1,562   3,663   11,149   18,426  Loss from operations (1,559)  (3,742)  (10,627)  (18,255) Interest (expense) income, net (1)  37   29   (448) Other expense, net —   (1)  (411)  (60) Net loss and comprehensive loss$(1,560) $(3,706) $(11,009) $(18,763) Net loss per share, basic and diluted$(0.20) $(0.61) $(1.42) $(5.07) Weighted-average common shares outstanding, basic and diluted 7,728,639   6,061,248   7,727,494   3,700,538  OBALON THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except shares and par value data) September 30, 2020 December 31, 2019 Assets (unaudited)      Current assets:        Cash and cash equivalents$5,514  $14,055  Accounts receivable, net —   285  Inventory —   1,936  Other current assets 3,517   1,959  Total current assets 9,031   18,235  Property and equipment, net 982   1,081  Lease right-of-use assets 646   1,077  Other long-term assets 1,303   —  Total assets$11,962  $20,393  Liabilities and Stockholders’ Equity        Current liabilities:        Accounts payable$656  $648  Accrued compensation 116   820  Deferred revenue 61   424  Other current liabilities 3,634   1,524  Current portion of lease liabilities 583   561  Total current liabilities 5,050   3,977  Lease liabilities, long-term 553   567  Long-term debt 430   —  Other long-term liabilities 7   —  Total long-term liabilities 990   567  Total liabilities 6,040   4,544  Commitments and contingencies        Stockholders’ equity:        Common stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 7,770,698 and 7,724,100 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively 8   8  Additional paid-in capital 189,353   188,271  Accumulated deficit (183,439)  (172,430) Total stockholders’ equity 5,922   15,849  Total liabilities and stockholders’ equity$11,962  $20,393  OBALON THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (in thousands) Nine Months Ended September 30,       2020  2019  Operating activities:        Net loss$(11,009) $(18,763) Adjustments to reconcile net loss to net cash used in operating activities:        Depreciation 260   361  Stock-based compensation 1,021   2,300  Issuance of cash-settled options 7   —  Issuance of warrants for the purchase of common stock 45   —  Loss on disposal of fixed assets —   128  Amortization of right-of-use assets 378   301  Accretion of investment discount, net —   (2) Amortization of debt discount —   70  Impairment of long-lived assets and other charges 1,257   —  Impairment of inventory 53   —  Change in operating assets and liabilities:        Accounts receivable, net 285   632  Inventory (524)  (117) Other long-term assets (9)  —  Other current assets (1,389)  1,604  Accounts payable 8   (724) Accrued compensation (688)  (3,097) Deferred revenue (363)  (69) Lease liabilities, net (293)  (248) Other current and long term liabilities 2,107   (363) Net cash used in operating activities (8,854)  (17,987) Investing activities:        Maturities of short-term investments —   2,550  Purchase of property and equipment (117)  (44) Net cash (used in) provided by investing activities (117)  2,506  Financing activities:        Proceeds from long-term loan 430   10,000  Payment on long-term loan —   (20,000) Proceeds from issuance of common and warrants, net of paid issuance costs —   15,014  Proceeds from issuance of common stock, net of issuance costs —   8,659  Proceeds from sale of common stock upon exercise of stock options —   1  Net cash provided by financing activities 430   13,674  Net decrease in cash and cash equivalents (8,541)  (1,807) Cash and cash equivalents at beginning of period 14,055   21,187  Cash and cash equivalents at end of period$5,514  $19,380  Supplemental cash flow information:        Interest paid$—  $700  Unpaid issuance costs$—  $295    CONTACT: For Obalon Therapeutics, Inc. Investor Contact: Andrew Rasdal President and Chief Executive Officer Obalon Therapeutics, Inc. Office: +1 844 362 2566 arasdal@obalon.com

  • GlobeNewswire

    Obalon Announces Consulting Agreement As Part of Strategy To Seek Coverage and Reimbursement for The Obalon Balloon System

    SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it has executed a consulting agreement with Blue Ox Healthcare Partners, LLC, a private equity firm focused on commercial-ready companies bringing technology enabled innovation to healthcare, especially those involved in precision health, healthcare delivery, and affordability. The agreement calls for Blue Ox to provide consulting services to Obalon, including helping Obalon to develop and implement an effective coverage and reimbursement-based go-to-market strategy. Activities will include an evaluation of the current clinical evidence of the Obalon Balloon System, consideration of health economic studies to define cost of care reductions for patients with diabetes and hypertension resulting from its use, and assessments and readying of strategies for successful commercialization with managed care companies and risk-based providers.Charles Kennedy, MD, Managing Partner and CEO of Blue Ox, commented, “The clinical literature shows that weight loss can result in diabetes remission in correctly selected patient populations. The Obalon weight loss solution has completed sufficient clinical trials to prove safety and effectiveness. We are excited to work with Obalon to help combat obesity and diabetes and show health plans and value-based providers the patient outcomes and economic gains that can result.”Obalon continued to reiterate that obtaining reimbursement is never certain and can take many years to achieve, and if achieved, may not be determinative of the Company’s success. If initial efforts with payers begin to bear success, Obalon would expect to need to raise additional capital to support those efforts.About Obalon Therapeutics, Inc.Obalon Therapeutics, Inc. (Nasdaq: OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. For more information, please visit http://www.obalon.com.About Blue Ox Healthcare Partners, LLCBlue Ox Healthcare Partners, LLC is a private equity firm focused on commercial-ready companies bringing technology enabled innovation to healthcare, especially those involved in precision health, healthcare delivery, and affordability. For more information, please visit www.blueoxhcp.com.Cautionary Statement Regarding Forward Looking StatementsThis press release contains forward-looking statements that are not purely historical regarding Obalon’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to new products and their potential benefits. All forward-looking statements and reasons why results might differ included in this press release are made as of the date of this release, based on information currently available to Obalon, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward looking statements. The risks and uncertainties that may cause actual results to differ materially from Obalon’s current expectations are more fully described in Obalon’s annual report on Form 10-K for the period ended December 31, 2019, periodic report on Form 10-Q for the period ended June 30, 2020 and its other reports, each as filed with the Securities and Exchange Commission. Except as required by law, Obalon assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results. CONTACT: For Obalon Therapeutics, Inc. Investor Contact: Andrew Rasdal President and Chief Executive Officer Obalon Therapeutics, Inc. Office: +1 844 362 2566 arasdal@obalon.com